Loading...
Market
What will be the next major development in glioma treatments by August 7, 2025?
2
Resolution / Starting Odds
New drug approval • 25%
Major clinical trial success • 25%
New treatment guidelines • 25%
Other • 25%
Announcements from pharmaceutical companies or medical journals
Story
FDA Approves Servier's Vorasidenib for Low-Grade Glioma
Aug 7, 2024, 12:28 AM
The U.S. Food and Drug Administration (FDA) has approved Servier's vorasidenib, branded as Voranigo, for the treatment of low-grade glioma, a type of brain cancer. The drug, originally developed by Agios Pharmaceuticals (AGIO) as AG-881, targets IDH-mutant glioma in patients aged 12 and older. Data from the phase 3 INDIGO trial demonstrated that vorasidenib significantly improved progression-free survival (PFS), with a median PFS of 27.7 months compared to 11.1 months for placebo, resulting in a 61% risk reduction. This approval marks a significant milestone for Servier, following its acquisition of the drug, and applies to two types of rare brain cancer.
View original story
Similar markets
Successful Phase I trial • 25%
FDA Fast Track designation • 25%
Publication of promising preclinical results • 25%
No major milestone achieved • 25%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted or delayed • 25%
Glioblastoma • 25%
Medulloblastoma • 25%
Astrocytoma • 25%
Other • 25%
Yes • 50%
No • 50%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Keck School of Medicine at USC • 25%
Cambridge University • 25%
A Canadian Institution • 25%
Other • 25%
Yes • 50%
No • 50%
Improved efficacy • 25%
Reduced side effects • 25%
Lower cost of treatment • 25%
Other • 25%
Government grants • 25%
Private investment • 25%
Pharmaceutical companies • 25%
Academic institutions • 25%